We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Read MoreHide Full Article
Key Takeaways
Lilly's Foundayo generated $98 million in its first full quarter on the market.
Foundayo's U.S. prescriber base rose to 36,000, while prescriptions nearly doubled in late July.
Lilly is pursuing Foundayo's diabetes indication and evaluating it in six additional phase III studies.
Eli Lilly and Company (LLY - Free Report) announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly’s new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April.
Foundayo (orforglipron) generated $98 million in sales in the second quarter, its first full quarter on the market. Lilly expects Foundayo to be a commercial game-changer for the company as oral pills are expected to be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Lilly’s Zepbound and rival Novo Nordisk’s (NVO - Free Report) Wegovy.
However, the second-quarter results show that Foundayo is still in the early stages of sampling, physician engagement and direct-to-consumer promotion, with its DTC expansion beginning in June and the Medicare GLP-1 Bridge program becoming effective in July. Some investors initially expected the drug to generate around $1.2 billion-$1.6 billion in sales in 2026. With only $98 million recorded in the second quarter, a substantial sequential increase in the third and fourth quarters will be required to meet the initial expectations.
What Should We Expect in H2 2026?
The second half of 2026 should be considerably more important for Foundayo than the first half. On the second-quarter conference call, Lilly said that the U.S. launch of Foundayo is gaining momentum, supported by physician education and commercial access secured across all three major pharmacy benefit managers or PBMs in June. The U.S. prescriber base expanded to 36,000 from 8,000 mentioned on the first-quarter call. Moreover, the Medicare GLP-1 Bridge program became effective in July, potentially improving access for eligible patients. On the second-quarter call, Lilly said that Foundayo’s prescriptions nearly doubled in the final week of July from a month earlier and Foundayo represented nearly one in four new starts.
Lilly is also continuing Foundayo’s international expansion. The pill is currently under regulatory review in more than 40 additional countries, with further approvals expected later this year. Lilly expects to launch Foundayo in most international markets by 2027.
Foundayo’s Multi-Indication Potential
Lilly expects Foundayo to become a multi-indication cardiometabolic opportunity. For the type II diabetes indication, Lilly has filed regulatory applications in several countries, including the United States, supported by the ACHIEVE phase III program. For several type II diabetes patients who prefer an oral option and have difficulty in reaching their glycemic targets, Foundayo has the potential to be a foundational daily oral treatment.
In addition to obesity and type II diabetes, Lilly is also evaluating Foundayo in six phase III studies for other diabetes and obesity-related diseases, with data from some of these expected later this year.
Foundayo's $98 million sales in the second quarter mark an early start for Lilly’s oral GLP-1, with the bigger test coming in the second half of 2026. Rising prescriptions, a broader U.S. prescriber base, expanded commercial access and the launch of the Medicare GLP-1 Bridge program could support stronger uptake. Lilly is also pursuing international expansion and additional indications, including type II diabetes. If Foundayo continues to gain traction, it could become an important third pillar of Lilly’s GLP-1 franchise alongside Mounjaro and Zepbound, giving the company an oral option across the growing obesity and diabetes markets.
Race to Make Oral Obesity Pill Intensifies
Novo Nordisk had gained approval for an oral version of its obesity drug, Wegovy, in December 2025 and launched the pill in January 2026. Novo Nordisk announced sales of around $500 million (DKK 3.22 billion) from the Wegovy oral pill in its second-quarter results announced on Aug 4. Total prescriptions for Wegovy pill reached around 2.9 million in the second quarter.
Novo Nordisk’s other novel oral candidate in its obesity pipeline is zenagamtide (previously amycretin), a single molecule combining GLP-1 + amylin, which is in phase III for obesity. Zenagamtide is being developed in both oral (tablet) and subcutaneous injection formulations.
While Lilly and Novo Nordisk currently dominate this space, smaller biotechs like Structure Therapeutics (GPCR - Free Report) and Viking Therapeutics (VKTX - Free Report) are also developing oral GLP-1 drugs for treating obesity.
Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.
Structure Therapeutics recently initiated the phase III ACCOMPLISH program on its once-daily oral small molecule GLP-1 receptor agonist, aleniglipron.
LLY’s Price Performance, Valuation and Estimates
Lilly’s stock has risen 13.5% so far this year compared with the industry’s increase of 12.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Lilly’s stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 29.30 forward earnings, higher than 18.73 for the industry. However, the stock is trading below its 5-year mean of 34.57.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 has risen from $35.38 to $35.60 per share over the past 30 days, while that for 2027 has risen from $44.93 to $45.49 per share over the same timeframe.
View the Zacks #1 Rank List
Image: Bigstock
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Key Takeaways
Eli Lilly and Company (LLY - Free Report) announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly’s new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April.
Foundayo (orforglipron) generated $98 million in sales in the second quarter, its first full quarter on the market. Lilly expects Foundayo to be a commercial game-changer for the company as oral pills are expected to be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Lilly’s Zepbound and rival Novo Nordisk’s (NVO - Free Report) Wegovy.
However, the second-quarter results show that Foundayo is still in the early stages of sampling, physician engagement and direct-to-consumer promotion, with its DTC expansion beginning in June and the Medicare GLP-1 Bridge program becoming effective in July. Some investors initially expected the drug to generate around $1.2 billion-$1.6 billion in sales in 2026. With only $98 million recorded in the second quarter, a substantial sequential increase in the third and fourth quarters will be required to meet the initial expectations.
What Should We Expect in H2 2026?
The second half of 2026 should be considerably more important for Foundayo than the first half. On the second-quarter conference call, Lilly said that the U.S. launch of Foundayo is gaining momentum, supported by physician education and commercial access secured across all three major pharmacy benefit managers or PBMs in June. The U.S. prescriber base expanded to 36,000 from 8,000 mentioned on the first-quarter call. Moreover, the Medicare GLP-1 Bridge program became effective in July, potentially improving access for eligible patients. On the second-quarter call, Lilly said that Foundayo’s prescriptions nearly doubled in the final week of July from a month earlier and Foundayo represented nearly one in four new starts.
Lilly is also continuing Foundayo’s international expansion. The pill is currently under regulatory review in more than 40 additional countries, with further approvals expected later this year. Lilly expects to launch Foundayo in most international markets by 2027.
Foundayo’s Multi-Indication Potential
Lilly expects Foundayo to become a multi-indication cardiometabolic opportunity. For the type II diabetes indication, Lilly has filed regulatory applications in several countries, including the United States, supported by the ACHIEVE phase III program. For several type II diabetes patients who prefer an oral option and have difficulty in reaching their glycemic targets, Foundayo has the potential to be a foundational daily oral treatment.
In addition to obesity and type II diabetes, Lilly is also evaluating Foundayo in six phase III studies for other diabetes and obesity-related diseases, with data from some of these expected later this year.
Foundayo's $98 million sales in the second quarter mark an early start for Lilly’s oral GLP-1, with the bigger test coming in the second half of 2026. Rising prescriptions, a broader U.S. prescriber base, expanded commercial access and the launch of the Medicare GLP-1 Bridge program could support stronger uptake. Lilly is also pursuing international expansion and additional indications, including type II diabetes. If Foundayo continues to gain traction, it could become an important third pillar of Lilly’s GLP-1 franchise alongside Mounjaro and Zepbound, giving the company an oral option across the growing obesity and diabetes markets.
Race to Make Oral Obesity Pill Intensifies
Novo Nordisk had gained approval for an oral version of its obesity drug, Wegovy, in December 2025 and launched the pill in January 2026. Novo Nordisk announced sales of around $500 million (DKK 3.22 billion) from the Wegovy oral pill in its second-quarter results announced on Aug 4. Total prescriptions for Wegovy pill reached around 2.9 million in the second quarter.
Novo Nordisk’s other novel oral candidate in its obesity pipeline is zenagamtide (previously amycretin), a single molecule combining GLP-1 + amylin, which is in phase III for obesity. Zenagamtide is being developed in both oral (tablet) and subcutaneous injection formulations.
While Lilly and Novo Nordisk currently dominate this space, smaller biotechs like Structure Therapeutics (GPCR - Free Report) and Viking Therapeutics (VKTX - Free Report) are also developing oral GLP-1 drugs for treating obesity.
Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.
Structure Therapeutics recently initiated the phase III ACCOMPLISH program on its once-daily oral small molecule GLP-1 receptor agonist, aleniglipron.
LLY’s Price Performance, Valuation and Estimates
Lilly’s stock has risen 13.5% so far this year compared with the industry’s increase of 12.6%.
From a valuation standpoint, Lilly’s stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 29.30 forward earnings, higher than 18.73 for the industry. However, the stock is trading below its 5-year mean of 34.57.
The Zacks Consensus Estimate for 2026 has risen from $35.38 to $35.60 per share over the past 30 days, while that for 2027 has risen from $44.93 to $45.49 per share over the same timeframe.
Lilly has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.